LAVA Therapeutics shares are trading higher after the company announced Janssen selected a lead gamma-delta T cell engager bispecific antibody to move toward clinical development.
Portfolio Pulse from Benzinga Newsdesk
LAVA Therapeutics' shares are trading higher after Janssen selected a lead gamma-delta T cell engager bispecific antibody from LAVA to move toward clinical development.
June 02, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LAVA Therapeutics shares are up after Janssen chose their gamma-delta T cell engager bispecific antibody for clinical development.
LAVA Therapeutics' stock price is likely to go up in the short term due to the positive news of Janssen selecting their gamma-delta T cell engager bispecific antibody for clinical development. This partnership and product advancement indicate potential growth and increased revenue for LAVA Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100